MTI (9438) Fundamentals 2026 — P/E 9.6x, Revenue Analysis | SniperIQ
MTI (9438) is a JP-listed Healthcare company in Medical - Healthcare Information Services with a market capitalization of ¥33.9B, trading at ¥611.00 on the JPX. This SniperIQ fundamentals page covers MTI's valuation (P/E 9.6x, P/B 1.7x), profitability (net margin 11.4%), revenue (¥29.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is MTI's market cap?
MTI (9438) has a market capitalization of approximately ¥33.9B, trading at ¥611.00 on the JPX. Market cap moves with the live share price.
What is MTI's P/E ratio?
MTI's trailing twelve-month P/E ratio is 9.6x, with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is MTI?
MTI runs a net profit margin of 11.4%, a gross margin of 73.6%, and an operating margin of 9.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does MTI generate?
MTI reported revenue of ¥29.9B for fiscal year 2025, with net income of ¥3.4B and earnings per share (EPS) of 61.62. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does MTI pay a dividend?
MTI offers a trailing dividend yield of about 3.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is MTI financially healthy?
MTI carries a debt-to-equity ratio of 0.07x and a current ratio of 3.46x, with a market beta of 0.12. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is MTI a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For MTI (9438) the key facts are: market cap ¥33.9B, P/E 9.6x, revenue ¥29.9B, 52-week range 527-948. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track MTI's full fundamentals live
Get MTI's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.